BACKGROUND: Nanoparticle-based systems are promising for the development of imaging and therapeutic agents. The main advantage of nanoparticles over traditional systems lies in the possibility of loading multiple functionalities onto a single molecule, which are useful for therapeutic and/or diagnostic purposes. These functionalities include targeting moieties which are able to recognize receptors overexpressed by specific cells and tissues. However, targeted delivery of nanoparticles requires an accurate system design. We present here a rationally designed, genetically engineered, and chemically modified protein-based nanoplatform for cell/tissue-specific targeting. METHODS: Our nanoparticle constructs were based on the heavy chain of the human protein ferritin (HFt), a highly symmetrical assembly of 24 subunits enclosing a hollow cavity. HFt-based nanoparticles were produced using both genetic engineering and chemical functionalization methods to impart several functionalities, ie, the α-melanocyte-stimulating hormone peptide as a melanoma-targeting moiety, stabilizing and HFt-masking polyethylene glycol molecules, rhodamine fluorophores, and magnetic resonance imaging agents. The constructs produced were extensively characterized by a number of physicochemical techniques, and assayed for selective melanoma-targeting in vitro and in vivo. RESULTS: Our HFt-based nanoparticle constructs functionalized with the α-melanocyte-stimulating hormone peptide moiety and polyethylene glycol molecules were specifically taken up by melanoma cells but not by other cancer cell types in vitro. Moreover, experiments in melanoma-bearing mice indicate that these constructs have an excellent tumor-targeting profile and a long circulation time in vivo. CONCLUSION: By masking human HFt with polyethylene glycol and targeting it with an α-melanocyte-stimulating hormone peptide, we developed an HFt-based melanoma-targeting nanoplatform for application in melanoma diagnosis and treatment. These results could be of general interest, because the same strategy can be exploited to develop ad hoc nanoplatforms for specific delivery towards any cell/tissue type for which a suitable targeting moiety is available.

Institute of Microbiology Academy of Sciences of the Czech Republic VVI Prague Czech Republic

Zobrazit více v PubMed

Poon Z, Chang D, Zhao X, Hammond PT. Layer-by-layer nanoparticles with a pH-sheddable layer for in vivo targeting of tumor hypoxia. ACS Nano. 2011;5(6):4284–4292. PubMed PMC

Kateb B, Chiu K, Black KL, et al. Nanoplatforms for constructing new approaches to cancer treatment, imaging, and drug delivery: what should be the policy? Neuroimage. 2011;54(Suppl 1):S106–124. PubMed PMC

Nie S. Understanding and overcoming major barriers in cancer nanomedicine. Nanomedicine. 2010;5(4):523–528. PubMed PMC

Armstead AL, Li B. Nanomedicine as an emerging approach against intracellular pathogens. Int J Nanomedicine. 2011;6(1):3281–3293. PubMed PMC

Tzeng SY, Yang PH, Grayson WL, Green JJ. Synthetic poly(ester amine) and poly(amido amine) nanoparticles for efficient DNA and siRNA delivery to human endothelial cells. Int J Nanomedicine. 2011;6(1):3309–3322. PubMed PMC

Bode SA, Minten IJ, Nolte RJ, Cornelissen JJ. Reactions inside nanoscale protein cages. Nanoscale. 2011;3(6):2376–2389. PubMed

Heddle JG. Protein cages, rings and tubes: useful components of future nanodevices? Nanotechnol Sci Appl. 2008;1:67–78. PubMed PMC

Chiancone E, Ceci P, Ilari A, Ribacchi F, Stefanini S. Iron and proteins for iron storage and detoxification. Biometals. 2004;17(3):197–202. PubMed

Watt RK. The many faces of the octahedral ferritin protein. Biometals. 2011;24(3):489–500. PubMed

Niemeyer CM, Ceyhan B. DNA-directed functionalization of colloidal gold with proteins. Angew Chem Int Ed Engl. 2001;40(19):3685–3688. PubMed

Uchida M, Kang S, Reichhardt C, Harlen K, Douglas T. The ferritin superfamily: supramolecular templates for materials synthesis. Biochim Biophys Acta. 2010;1800(8):834–845. PubMed PMC

Dominguez-Vera JM, Fernandez B, Galvez N. Native and synthetic ferritins for nanobiomedical applications: recent advances and new perspectives. Future Med Chem. 2010;2(4):609–618. PubMed

Kasyutich O, Ilari A, Fiorillo A, Tatchev D, Hoell A, Ceci P. Silver ion incorporation and nanoparticle formation inside the cavity of Pyrococcus furiosus ferritin: structural and size-distribution analyses. J Am Chem Soc. 2010;132(10):3621–3627. PubMed

Li M, Viravaidya C, Mann S. Polymer-mediated synthesis of ferritin-encapsulated inorganic nanoparticles. Small. 2007;3(9):1477–1481. PubMed

Ueno T, Suzuki M, Goto T, Matsumoto T, Nagayama K, Watanabe Y. Size-selective olefin hydrogenation by a Pd nanocluster provided in an apoferritin cage. Angew Chem Int Ed Engl. 2004;43(19):2527–2530. PubMed

Yoshimura H. Protein-assisted nanoparticle synthesis. Colloids Surf A. 2006;(0):282–283. 464–470.

Yamashita I. Biosupramolecules for nanodevices: biomineralization of nanoparticles and their applications. J Mater Chem. 2008;18(32):3813–3820.

Kostiainen MA, Ceci P, Fornara M, et al. Hierarchical self-assembly and optical disassembly for controlled switching of magnetoferritin nanoparticle magnetism. ACS Nano. 2011;5(8):6394–6402. PubMed

Bakoush O, Tencer J, Tapia J, Rippe B, Torffvit O. Higher urinary IgM excretion in type 2 diabetic nephropathy compared to type 1 diabetic nephropathy. Kidney Int. 2002;61(1):203–208. PubMed

Jain RK. Delivery of molecular and cellular medicine to solid tumors. Adv Drug Deliv Rev. 2001;46(1–3):149–168. PubMed

Uchida M, Willits DA, Muller K, et al. Intracellular distribution of macrophage targeting ferritin-iron oxide nanocomposite. Adv Mater. 2009;21(4):458–462.

Valero E, Tambalo S, Marzola P, et al. Magnetic nanoparticle-templated assembly of protein subunits: a new platform for carbohydrate-based MRI nanoprobes. J Am Chem Soc. 2011;133(13):4889–4895. PubMed

Geninatti CS, Crich S, Bussolati B, et al. Magnetic resonance visualization of tumor angiogenesis by targeting neural cell adhesion molecules with the highly sensitive gadolinium-loaded apoferritin probe. Cancer Res. 2006;66(18):9196–9201. PubMed

Lin X, Xie J, Niu G, et al. Chimeric ferritin nanocages for multiple function loading and multimodal imaging. Nano Lett. 2011;11(2):814–819. PubMed PMC

Xing R, Wang X, Zhang C, et al. Characterization and cellular uptake of platinum anticancer drugs encapsulated in apoferritin. J Inorg Biochem. 2009;103(7):1039–1044. PubMed

Uchida M, Flenniken ML, Allen M, et al. Targeting of cancer cells with ferrimagnetic ferritin cage nanoparticles. J Am Chem Soc. 2006;128(51):16626–16633. PubMed

Barreto JA, O’Malley W, Kubeil M, Graham B, Stephan H, Spiccia L. Nanomaterials: applications in cancer imaging and therapy. Adv Mater. 2011;23(12):H18–40. PubMed

Worwood M, Cragg SJ, Williams AM, Wagstaff M, Jacobs A. The clearance of 131I-human plasma ferritin in man. Blood. 1982;60(4):827–833. PubMed

Chen TT, Li L, Chung DH, et al. TIM-2 is expressed on B cells and in liver and kidney and is a receptor for H-ferritin endocytosis. J Exp Med. 2005;202(7):955–965. PubMed PMC

Uchida M, Terashima M, Cunningham CH, et al. A human ferritin iron oxide nano-composite magnetic resonance contrast agent. Magn Reson Med. 2008;60(5):1073–1081. PubMed

Mack U, Storey EL, Powell LW, Halliday JW. Characterization of the binding of ferritin to the rat liver ferritin receptor. Biochim Biophys Acta. 1985;843(3):164–170. PubMed

Fisher J, Devraj K, Ingram J, et al. Ferritin: a novel mechanism for delivery of iron to the brain and other organs. Am J Physiol Cell Physiol. 2007;293(2):C641–649. PubMed

Anderson JG, Ramm GA, Halliday WJ, Powell WL. Ferritin metabolism in hemochromatosis. In: Barton JC, Edwards CQ, editors. Hemochromatosis: Genetics, Pathophysiology, Diagnosis and Treatment. Cambridge, UK: Cambridge University Press; 2000.

Fittipaldi M, Innocenti C, Ceci P, et al. Looking for quantum effects in magnetic nanoparticles using the molecular nanomagnet approach. Physical Review B. 2011;83(10):104409.

Benada O, Pokorny V. Modification of the Polaron sputter-coater unit for glow-discharge activation of carbon support films. J Electron Microsc Tech. 1990;16(3):235–239. PubMed

Berman HM, Westbrook J, Feng Z, et al. The protein data bank. Nucleic Acids Res. 2000;28(1):235–242. PubMed PMC

Ballou B, Lagerholm BC, Ernst LA, Bruchez MP, Waggoner AS. Noninvasive imaging of quantum dots in mice. Bioconjug Chem. 2004;15(1):79–86. PubMed

Raha S, Paunesku T, Woloschak G. Peptide-mediated cancer targeting of nanoconjugates. Wiley Interdiscip Rev Nanomed Nanobiotechnol. 2011;3(3):269–281. PubMed PMC

Miao Y, Whitener D, Feng W, Owen NK, Chen J, Quinn TP. Evaluation of the human melanoma targeting properties of radiolabeled alpha-melanocyte stimulating hormone peptide analogues. Bioconjug Chem. 2003;14(6):1177–1184. PubMed

Tatro JB, Atkins M, Mier JW, et al. Melanotropin receptors demonstrated in situ in human melanoma. J Clin Invest. 1990;85(6):1825–1832. PubMed PMC

Miao Y, Quinn TP. Peptide-targeted radionuclide therapy for melanoma. Crit Rev Oncol Hematol. 2008;67(3):213–228. PubMed PMC

Balch CM, Soong SJ, Gershenwald JE, et al. Prognostic factors analysis of 17,600 melanoma patients: validation of the American Joint Committee on Cancer melanoma staging system. J Clin Oncol. 2001;19(16):3622–3634. PubMed

Lu W, Xiong C, Zhang G, et al. Targeted photothermal ablation of murine melanomas with melanocyte-stimulating hormone analog-conjugated hollow gold nanospheres. Clin Cancer Res. 2009;15(3):876–886. PubMed PMC